Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Other Non-Current Liabilities (2023)

Historic Other Non-Current Liabilities for Tonix Pharmaceuticals Holding (TNXP) over the last 1 years, with Q4 2023 value amounting to $14.6 million.

  • Tonix Pharmaceuticals Holding's Other Non-Current Liabilities changed N/A to $14.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was $14.6 million, marking a year-over-year change of. This contributed to the annual value of $14.6 million for FY2023, which is N/A changed from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Other Non-Current Liabilities stood at $14.6 million for Q4 2023.
  • Tonix Pharmaceuticals Holding's Other Non-Current Liabilities' 5-year high stood at $14.6 million during Q4 2023, with a 5-year trough of $14.6 million in Q4 2023.